10.6.2008 – 10.8.2008: Therapeutic Monoclonal Antibody Discovery - Greg Lazar, Ph.D., presenting; Cambridge, MA
Among the most innovative new drugs on the market, antibody and protein biotherapeutics are changing the way physicians treat cancer, inflammation, and autoimmune disease. At Xencor, we make better biotherapeutics candidates by engineering antibodies and proteins to be potent treatments of life-threatening and debilitating diseases. Our unique Protein Design Automation® suite of technologies allows us to systematically shape the clinical performance of protein-based drug leads to produce new drug candidates for development and commercialization by ourselves and by major life science and pharmaceutical partners.